WHO Chief Tedros Says Received First Expression Of Interest For Emergency Use Listing From Mpox Diagnostics Manufacturer; WHO Officials Discuss Polio Vaccination Plan In Gaza, Confirm Applications From Bavarian Nordic And KM Biologics For Mpox Vaccines Emergency Use Listing, And Announce 230,000 Doses Available For Congo
Portfolio Pulse from Benzinga Newsdesk
The WHO has received its first expression of interest for emergency use listing from a Mpox diagnostics manufacturer. WHO officials also discussed polio vaccination plans in Gaza and confirmed applications from Bavarian Nordic and KM Biologics for Mpox vaccines emergency use listing, with 230,000 doses available for Congo.
August 30, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bavarian Nordic has applied for emergency use listing of its Mpox vaccine with the WHO, which could lead to increased demand and stock price if approved.
Bavarian Nordic's application for emergency use listing with the WHO suggests potential for increased demand for its Mpox vaccine, which could positively impact its stock price if approved.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
KM Biologics has applied for emergency use listing of its Mpox vaccine with the WHO, which could lead to increased demand and stock price if approved.
KM Biologics' application for emergency use listing with the WHO suggests potential for increased demand for its Mpox vaccine, which could positively impact its stock price if approved.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80